Recent studies have shown that cytotoxic doses of naringin (76.21 μM and 64.42 μM) effectively induce cell cycle arrest and apoptosis and inhibit epithelial–mesenchymal transition (EMT) by targeting the PI3K–AKT/Zeb1 pathway in gastric cancer cells (MGC803 and MKN45) [125]. Here, AKT1 is linked to gastric cancer.